Transduction and expansion of cells

Patent metadata

Field	Value
Publication number	US-12577534-B2
Application number	US-201916977346-A
Country	US
Kind code	B2
Filing date	Feb 28, 2019
Priority date	Mar 1, 2018
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

Provided is a method of transducing and expanding a population of cells, the method comprising, in order: a cell selection step; a pre-transduction activation step; a cell transduction step; and a cell expansion phase. At least the cell transduction step and the expansion phase comprise incubation of the cells with IL-15. The methods of the invention are well suited to the transduction and expansion of populations of cells expressing chimeric antigen receptors (CARs), and in particular for the transduction and expansion of populations of invariant natural killer T (iNKT) cells expressing CARs. Also provided are populations of cells produced by the methods of the invention, and pharmaceutical compositions comprising populations of cells, as well medical uses of the pharmaceutical compositions and populations of cells. The cells and pharmaceutical composition are suitable for application in medical use and methods of treatment, including immunotherapy.

First claim

We claim:

1 . A method of transducing and expanding a population of invariant Natural Killer T (INKT) cells, the method comprising, in order:
a. an INKT cell selection step; b. a pre-transduction activation step; c. a cell transduction step; and d. a cell expansion phase; wherein at least the pre-transduction activation step, the cell transduction step and the cell expansion phase comprise incubation of the iNKT cells with IL-15, wherein the iNKT cells comprise the Vα24Jα18 TCR chain, wherein the pre-transduction activation step comprises activation by incubation of the iNKT cells with anti-CD3 and anti-CD28, and wherein the cell transduction step is performed within 24-48 hours from the end of the iNKT cell selection step.

2 . The method according to claim 1 , wherein the pre-transduction activation step further comprises providing IL-15 at a concentration of approximately 30 IU/ml within a medium in which pre-transduction activation is effected.

3 . The method according to claim 1 , wherein the pre-transduction activation step is practiced between 12 and 24 hours prior to the transduction step.

4 . The method according to claim 1 , further comprising one or more additional steps or phases, independently selected from the group consisting of:
e. a lymphocyte enrichment step; f. a transduced cell selection step; g. a transduced cell activation step; and h. a further cell expansion phase.

5 . The method according to claim 4 , wherein the lymphocyte enrichment step is performed within 24 hours from collection or thawing.

6 . The method according to claim 1 , wherein the iNKT cell selection step is used to produce a population of cells that comprises at least 80% iNKT cells.

7 . The method according to claim 6 , wherein the iNKT cell selection step comprises a magnetic activated cell sorting step.

8 . The method according to claim 1 , wherein the iNKT cells are transduced to express a non-native molecule selected from the group consisting of a CAR; and a CAAR.

9 . The method according to claim 1 , wherein the iNKT cell selection step is performed immediately after completion of a preceding step, or immediately after collection or thawing if it constitutes the first step of the claimed method.

10 . The method according to claim 1 , wherein the pre-transduction activation step is performed within two hours of completion of the iNKT cell selection step.

11 . The method according to claim 1 , wherein the cell transduction step is performed within 24-36 hours from the end of the iNKT cell selection step.

12 . The method according to claim 1 , wherein the cell expansion phase begins immediately after the cell transduction step is completed.

13 . The method according to claim 1 , wherein the method comprises a transduced cell activation step, and the cell expansion phase has a duration of between 5-7 days.

14 . The method according to claim 1 , wherein the method does not comprise a transduced cell activation step, and the cell expansion phase has a duration of around three weeks.

15 . A method of transducing and expanding a population of invariant Natural Killer T (INKT) cells comprising, in order:
a. a lymphocyte enrichment step; b. an iNKT cell selection step; c. a pre-transduction iNKT cell activation step; d. an INKT cell transduction step; e. a first transduced iNKT cell expansion phase; f. a transduced INKT cell selection step; g. a transduced INKT cell activation step; and h. a further transduced iNKT cell expansion phase; wherein, all of the steps and phases from the pre-transduction INKT cell activation step onwards are carried out in the presence of IL-15, wherein the INKT cells comprise the Vα24Jα18 TCR chain, wherein the pre-transduction iNKT cell activation step comprises activation by incubation of the iNKT cells with anti-CD3 and anti-CD28, and wherein the iNKT cell transduction step is performed within 24-48 hours from the end of the INKT cell selection step.

Assignees

• Imperial College Innovations Ltd

Inventors

• Karadimitris Anastasios
• Rotolo Antonia

Classifications

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/4202

  Receptors, cell surface antigens or cell surface determinants · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K2239/29

  Multispecific CARs · CPC title